Cutera (Nasdaq:CUTR) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

CUTR Overzicht aandelen

Cutera, Inc. biedt esthetische en dermatologische oplossingen voor artsen over de hele wereld.

CUTR fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	0/6
Dividenden	0/6

Beloningen

Risicoanalyse

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Heeft minder dan 1 jaar cash runway

Negatief eigen vermogen

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

+ 1 meer risico

Cutera, Inc. Concurrenten

QT Imaging Holdings

NasdaqGS:QTI

US$15.2m

Cue Health

NasdaqCM:HLTH

US$14.7m

Scientific Industries

OTCPK:SCND

US$13.5m

NeurAxis

NYSEAM:NRXS

US$20.4m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Cutera
Historische aandelenkoersen
Huidige aandelenkoers	US$0.79
52 Week Hoogtepunt	US$5.31
52 Week Laag	US$0.65
Bèta	1.33
11 maand verandering	4.22%
3 maanden verandering	-38.60%
1 Jaar Verandering	-83.18%
33 jaar verandering	-98.21%
5 jaar verandering	-97.11%
Verandering sinds IPO	-94.34%

Recent nieuws en updates

Cutera, Inc. (NASDAQ:CUTR) Looks Inexpensive After Falling 47% But Perhaps Not Attractive Enough

Aug 20

Recent updates

Cutera, Inc. (NASDAQ:CUTR) Looks Inexpensive After Falling 47% But Perhaps Not Attractive Enough

Aug 20

Revenues Working Against Cutera, Inc.'s (NASDAQ:CUTR) Share Price Following 28% Dive

Jun 22

Revenues Working Against Cutera, Inc.'s (NASDAQ:CUTR) Share Price Following 35% Dive

Mar 14

Analysts Are More Bearish On Cutera, Inc. (NASDAQ:CUTR) Than They Used To Be

Aug 11

An Intrinsic Calculation For Cutera, Inc. (NASDAQ:CUTR) Suggests It's 48% Undervalued

Apr 19

Cutera, Inc. (NASDAQ:CUTR) Shares Could Be 49% Below Their Intrinsic Value Estimate

Sep 01

Cutera: The 'AviClear' Sign To Get Bullish

Jun 22

Cutera (NASDAQ:CUTR) Is Carrying A Fair Bit Of Debt

May 27

Returns On Capital Signal Tricky Times Ahead For Cutera (NASDAQ:CUTR)

Apr 22

Cutera: Gains Aren't Surprising After Acne Laser Therapy Cleared

Mar 31

Rendement voor aandeelhouders

	CUTR	US Medical Equipment	US Markt
7D	10.0%	-0.6%	-0.4%
1Y	-83.2%	22.6%	34.1%

Rendement versus industrie: CUTR presteerde slechter dan de US Medical Equipment -sector, die het afgelopen jaar een rendement van 22.6 % opleverde.

Rendement versus markt: CUTR presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 34.1 % opleverde.

Prijsvolatiliteit

Is CUTR's price volatile compared to industry and market?
CUTR volatility
CUTR Average Weekly Movement	17.0%
Medical Equipment Industry Average Movement	8.5%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van CUTR is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 17% ) van CUTR is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1998	430	Taylor Harris	www.cutera.com

Cutera, Inc. biedt esthetische en dermatologische oplossingen voor artsen wereldwijd. Het ontwikkelt, produceert en verkoopt op energie gebaseerde productplatforms voor artsen en distribueert door derden geproduceerde huidverzorgingsproducten. Het bedrijf biedt AviClear voor de behandeling van milde, matige en ernstige inflammatoire acne vulgaris; Secret PRO, een apparaat dat gebruik maakt van gefractioneerde CO2 voor huidresurfacing en radiofrequentie (RF) microneedling voor huidrevitalisatie; truFlex, een apparaat voor bio-elektrische spierstimulatie dat is ontworpen om de buik, billen en dijen te verstevigen; en excel V/V+, een vasculair en goedaardig gepigmenteerd laesiebehandelingsplatform.

Cutera, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Cutera zich tot de beurswaarde?
CUTR fundamentele statistieken
Marktkapitalisatie	US$15.98m
Inkomsten(TTM)	-US$148.97m
Inkomsten(TTM)	US$169.19m

0.1x

P/S-verhouding

-0.1x

Koers/Winstverhouding

Is CUTR overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
CUTR resultatenrekening (TTM)
Inkomsten	US$169.19m
Kosten van inkomsten	US$155.35m
Brutowinst	US$13.84m
Overige uitgaven	US$162.81m
Inkomsten	-US$148.97m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-7.35
Brutomarge	8.18%
Nettowinstmarge	-88.05%
Schuld/Eigen Vermogen Verhouding	-194.7%

Hoe presteerde CUTR op de lange termijn?

Bekijk historische prestaties en vergelijking

CUTR Overzicht aandelen

Beloningen

Risicoanalyse

Cutera, Inc. Concurrenten

NasdaqGS:QTI

US$15.2m

NasdaqCM:HLTH

US$14.7m

OTCPK:SCND

US$13.5m

NYSEAM:NRXS

US$20.4m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Cutera Receives Deficiency Notice from Nasdaq Regarding Listing Rule 5450(a)(1)

Cutera, Inc. (NASDAQ:CUTR) Looks Inexpensive After Falling 47% But Perhaps Not Attractive Enough

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Cutera, Inc. Revises Revenue Guidance for the Year 2024

High number of new and inexperienced directors

Cutera, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Recent updates

Cutera Receives Deficiency Notice from Nasdaq Regarding Listing Rule 5450(a)(1)

Cutera, Inc. (NASDAQ:CUTR) Looks Inexpensive After Falling 47% But Perhaps Not Attractive Enough

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Cutera, Inc. Revises Revenue Guidance for the Year 2024

High number of new and inexperienced directors

Cutera, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Cutera, Inc.(NasdaqGS:CUTR) dropped from Russell 3000 Index

Revenues Working Against Cutera, Inc.'s (NASDAQ:CUTR) Share Price Following 28% Dive

Price target decreased by 17% to US$6.33

High number of new and inexperienced directors

Cutera, Inc., Annual General Meeting, Jul 15, 2024

Cutera, Inc. Reiterates Earnings Guidance for 2024

Cutera, Inc. to Report Q1, 2024 Results on May 09, 2024

Cutera, Inc. Announces North America Launch of xeo+

Cutera, Inc. Provides Revenue Guidance for the Full Year 2024

Cutera, Inc. announced delayed annual 10-K filing

Revenues Working Against Cutera, Inc.'s (NASDAQ:CUTR) Share Price Following 35% Dive

Consensus EPS estimates fall by 33%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Cutera, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Price target decreased by 59% to US$7.67

High number of new and inexperienced directors

Cutera, Inc. Revises Revenue Guidance for the Full Year 2023

Cutera, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Annual Report on Form 10-Q

Cutera, Inc. announced delayed 10-Q filing

Cutera, Inc. Announces Resignation of Juliane Park from the Board of Directors, Effective as of December 1, 2023

Cutera, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Janet Widmann Resigns from the Board of Directors of Cutera, Inc. Effective November 1, 2023

New minor risk - Market cap size

Cutera, Inc. Appoints Brent Hauser as President, International

Cutera, Inc. Announces the Launch of New Skin Resurfacing and Revitalization Platform Secret DUO

President recently bought US$297k worth of stock

Cutera, Inc. Appoints Jeffrey Jones as Chief Operating Officer, Effective August 28, 2023

Consensus revenue estimates fall by 14%

Analysts Are More Bearish On Cutera, Inc. (NASDAQ:CUTR) Than They Used To Be

New major risk - Share price stability

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 8.9% to US$23.00

Cutera, Inc. Provides Revenue Guidance for the Full Year 2023

Cutera, Inc. Appoints Talyor C. Harris as President, Effective August 7, 2023

Cutera, Inc. Announces CEO Changes, Effective August 7, 2023

Cutera, Inc. to Report Q2, 2023 Results on Aug 08, 2023

the Gross Law Firm Notifies Shareholders of Cutera, Inc. of A Class Action Lawsuit and A Lead Plaintiff Deadline of July 24, 2023

Cutera, Inc. Announces A New U.S. Food and Drug Administration Clearance of AviClear as A Long-Term Treatment for Mild to Severe Inflammatory Acne Vulgaris

Cutera, Inc. Announces Resignation of J. Daniel Plants as Director

Independent Director notifies of intention to sell stock

Cutera, Inc. Announces Resignation of Joseph E. Whitters from the Board of Directors

Kessler Topaz Meltzer & Check, LLP Files a Securities Fraud Class Action Lawsuit Against Cutera, Inc

Less than half of directors are independent

Cutera, Inc. Announces Board Changes

Cutera, Inc. Appoints Stuart Drummond as Interim Chief Financial Officer

Voce Capital and David Mowry Terminate Proxy Solicitation

Cutera, Inc. Announces Chief Financial Officer Changes

First quarter 2023 earnings: EPS and revenues miss analyst expectations

An Intrinsic Calculation For Cutera, Inc. (NASDAQ:CUTR) Suggests It's 48% Undervalued

Full year 2022 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 57%

Now 21% undervalued after recent price drop

Full year 2022 earnings: EPS misses analyst expectations